



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

12th August 2015 - New research

TRANSDERMAL ROTIGOTINE - CLINICAL TRIAL RESULTS

Transdermal rotigotine, which is marketed as Neupro, is a dopamine receptor agonist that is used in the treatment of Parkinson's Disease. It offers the potential for continuous dopaminergic stimulation that could avoid the fluctuations observed with traditional forms of dopamine agonists. Neupro provides continuous delivery for 24 hours following application of the patch to intact skin. For more information go to : <https://www.neupro.com/> and <http://www.rxlist.com/neupro-drug.htm>



Rotigotine made hardly any difference to the Non-motor symptom score in Parkinson's Disease. However, improvements were detected in mood and apathy. General symptom improvements and the PDQ-39 scores also favoured rotigotine. Transdermal rotigotine also improved swallowing. There was a significantly greater reduction in the off-time when using rotigotine. Adverse events reported more frequently with rotigotine were nausea, application site reactions, somnolence and headache. Serious adverse events were only uncommonly reported.

References : European Journal of Neurology [2015] Jun 22 [Epub ahead of print] (A.Antonini, L.Bauer, E.Dohin, W.H.Oertel, O.Rascol, H.Reichmann, M.Schmid, P.Singh, E.Tolosa, K.R.Chaudhuri) <http://www.ncbi.nlm.nih.gov/pubmed/26095948>; Dysphagia [2015] May 13 [Epub ahead of print] (M.Hirano, C.Isono, H.Sakamoto, S.Ueno, S.Kusunoki, Y.Nakamura) <http://www.ncbi.nlm.nih.gov/pubmed/25966655>; Journal of Neurology [2014] 261 (10) : 1887-1893 (M.Nomoto, Y.Mizuno, T.Kondo, K.Hasegawa, M. Murata, M. Takeuchi, J.Ikeda, T.Tomida, N.Hattori) <http://www.ncbi.nlm.nih.gov/pubmed/25022939>

<http://www.viartis.net/parkinsons.disease/news/150812.pdf>

mail@viartis.net

©2015 Viartis